vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $173.1M, roughly 1.9× VARONIS SYSTEMS INC). On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 26.9%). VARONIS SYSTEMS INC produced more free cash flow last quarter ($49.0M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.

MDGL vs VRNS — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.9× larger
MDGL
$321.1M
$173.1M
VRNS
Growing faster (revenue YoY)
MDGL
MDGL
+183.9% gap
MDGL
210.8%
26.9%
VRNS
More free cash flow
VRNS
VRNS
$182.9M more FCF
VRNS
$49.0M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MDGL
MDGL
VRNS
VRNS
Revenue
$321.1M
$173.1M
Net Profit
$-58.6M
Gross Margin
76.0%
Operating Margin
-18.6%
-1.7%
Net Margin
-18.2%
Revenue YoY
210.8%
26.9%
Net Profit YoY
1.4%
EPS (diluted)
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
VRNS
VRNS
Q1 26
$173.1M
Q4 25
$321.1M
$173.4M
Q3 25
$287.3M
$161.6M
Q2 25
$212.8M
$152.2M
Q1 25
$137.3M
$136.4M
Q4 24
$103.3M
$158.5M
Q3 24
$62.2M
$148.1M
Q2 24
$130.3M
Net Profit
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
$-58.6M
$-27.8M
Q3 25
$-114.2M
$-29.9M
Q2 25
$-42.3M
$-35.8M
Q1 25
$-73.2M
$-35.8M
Q4 24
$-59.4M
$-13.0M
Q3 24
$-107.0M
$-18.3M
Q2 24
$-23.9M
Gross Margin
MDGL
MDGL
VRNS
VRNS
Q1 26
76.0%
Q4 25
78.9%
Q3 25
78.2%
Q2 25
79.5%
Q1 25
96.7%
78.7%
Q4 24
83.6%
Q3 24
83.8%
Q2 24
82.8%
Operating Margin
MDGL
MDGL
VRNS
VRNS
Q1 26
-1.7%
Q4 25
-18.6%
-17.5%
Q3 25
-39.7%
-22.2%
Q2 25
-22.2%
-24.0%
Q1 25
-57.8%
-32.1%
Q4 24
-64.8%
-11.1%
Q3 24
-187.1%
-16.0%
Q2 24
-22.1%
Net Margin
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
-18.2%
-16.0%
Q3 25
-39.8%
-18.5%
Q2 25
-19.9%
-23.5%
Q1 25
-53.4%
-26.2%
Q4 24
-57.5%
-8.2%
Q3 24
-172.0%
-12.4%
Q2 24
-18.4%
EPS (diluted)
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
$-2.55
$-0.23
Q3 25
$-5.08
$-0.26
Q2 25
$-1.90
$-0.32
Q1 25
$-3.32
$-0.32
Q4 24
$-2.50
$-0.12
Q3 24
$-4.92
$-0.16
Q2 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
VRNS
VRNS
Cash + ST InvestmentsLiquidity on hand
$198.7M
$179.3M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$453.5M
Total Assets
$1.3B
$1.6B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
VRNS
VRNS
Q1 26
$179.3M
Q4 25
$198.7M
$883.7M
Q3 25
$295.7M
$671.3M
Q2 25
$186.2M
$770.9M
Q1 25
$183.6M
$567.6M
Q4 24
$100.0M
$529.0M
Q3 24
$232.7M
$844.8M
Q2 24
$582.5M
Total Debt
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
MDGL
MDGL
VRNS
VRNS
Q1 26
$453.5M
Q4 25
$602.7M
$598.7M
Q3 25
$625.7M
$604.8M
Q2 25
$696.0M
$341.5M
Q1 25
$710.6M
$367.7M
Q4 24
$754.4M
$455.7M
Q3 24
$777.2M
$428.6M
Q2 24
$458.6M
Total Assets
MDGL
MDGL
VRNS
VRNS
Q1 26
$1.6B
Q4 25
$1.3B
$1.8B
Q3 25
$1.4B
$1.7B
Q2 25
$1.0B
$1.6B
Q1 25
$996.6M
$1.6B
Q4 24
$1.0B
$1.7B
Q3 24
$1.1B
$1.5B
Q2 24
$1.1B
Debt / Equity
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
VRNS
VRNS
Operating Cash FlowLast quarter
$-133.5M
$55.0M
Free Cash FlowOCF − Capex
$-133.8M
$49.0M
FCF MarginFCF / Revenue
-41.7%
28.3%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$118.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
VRNS
VRNS
Q1 26
$55.0M
Q4 25
$-133.5M
$24.7M
Q3 25
$79.8M
$33.4M
Q2 25
$-47.1M
$21.3M
Q1 25
$-88.9M
$68.0M
Q4 24
$-104.5M
$24.3M
Q3 24
$-67.0M
$22.5M
Q2 24
$11.7M
Free Cash Flow
MDGL
MDGL
VRNS
VRNS
Q1 26
$49.0M
Q4 25
$-133.8M
$20.7M
Q3 25
$79.0M
$30.4M
Q2 25
$18.0M
Q1 25
$65.7M
Q4 24
$-104.7M
$19.9M
Q3 24
$-67.8M
$21.3M
Q2 24
$10.9M
FCF Margin
MDGL
MDGL
VRNS
VRNS
Q1 26
28.3%
Q4 25
-41.7%
12.0%
Q3 25
27.5%
18.8%
Q2 25
11.8%
Q1 25
48.1%
Q4 24
-101.3%
12.6%
Q3 24
-109.0%
14.4%
Q2 24
8.4%
Capex Intensity
MDGL
MDGL
VRNS
VRNS
Q1 26
Q4 25
0.1%
2.3%
Q3 25
0.3%
1.8%
Q2 25
0.0%
2.2%
Q1 25
0.0%
1.7%
Q4 24
0.2%
2.7%
Q3 24
1.3%
0.8%
Q2 24
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

VRNS
VRNS

SaaS$161.1M93%
Term license subscriptions$6.9M4%
Maintenance and services$5.2M3%

Related Comparisons